# Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

> **NCT07479732** · PHASE1,PHASE2 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Osteosarcoma
- Osteosarcoma Metastatic

## Interventions

- **DRUG:** Liposomal Irinotecan
- **DRUG:** Apatinib in arm1

## Key facts

- **NCT ID:** NCT07479732
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2027-03-05
- **Final completion:** 2028-01-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07479732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07479732, "Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07479732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*